KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Learn how eczema presents differently on skin of color and the impact on mental health. Find resources for identification, ...

Rocatinlimab, administered subcutaneously, results in clinically meaningful improvements in patients with moderate-to-severe ...

Rocatinlimab improved moderate to severe dermatitis in adults, establishing the OX40 receptor as a validated treatment target ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Kymera Therapeutics, Inc. (NASDAQ:KYMR) ...

Kymera Therapeutics has announced positive results from its trial of KT-621 to treat patients with moderate to severe atopic ...

The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

They have access to pricey treatments and state-of-the-art tools, but here’s what they told us makes the biggest difference ...

As the body’s first line of defense, the skin performs multiple vital functions—it safeguards internal organs, regulates body ...

The FDA’s approval of Waskyra marks a historic breakthrough in treating Wiskott–Aldrich syndrome, a rare and life-threatening ...